Scarica l'app Stockscreener
55.13
0.47%
-0.26
Dopo l'orario di chiusura:
54.94
-0.19
-0.34%
Precedente Chiudi:
$55.39
Aprire:
$54.18
Volume 24 ore:
145.05K
Relative Volume:
0.57
Capitalizzazione di mercato:
$368.94M
Reddito:
-
Utile/perdita netta:
$-13.72M
Rapporto P/E:
-27.76
EPS:
-1.9861
Flusso di cassa netto:
$-12.20M
1 W Prestazione:
+1.04%
1M Prestazione:
+3.10%
6M Prestazione:
-43.29%
1 anno Prestazione:
+43.08%
Intervallo 1D:
$53.99
$57.30
Intervallo di 1 settimana:
$51.66
$60.00
Portata 52W:
$26.05
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
55.13 | 368.94M | 0 | -13.72M | -12.20M | -1.9861 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Iniziato | Morgan Stanley | Overweight |
| 2025-11-14 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | Iniziato | Leerink Partners | Outperform |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-09-09 | Iniziato | BTIG Research | Buy |
| 2025-09-03 | Iniziato | Oppenheimer | Outperform |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-08-26 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-19 | Ripresa | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Piper Sandler | Overweight |
| 2024-10-11 | Iniziato | Rodman & Renshaw | Buy |
| 2021-01-28 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
Gains Report: Will Monopar Therapeutics Inc benefit from sector rotationQuarterly Trade Review & Long Hold Capital Preservation Plans - baoquankhu1.vn
Trading Systems Reacting to (MNPR) Volatility - Stock Traders Daily
MNPR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Monopar Therapeutics Inc. (1IY0.SG) stock price, news, quote and history - Yahoo Finance Singapore
Monopar Therapeutics Inc. (1IY0.SG) - Yahoo! Finance Canada
[Form 4] Monopar Therapeutics Insider Trading Activity - Stock Titan
Monopar Therapeutics (MNPR) COO gains shares through RSU vesting and tax withholding - Stock Titan
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - ChartMill
Monopar Therapeutics Inc. 2025 Annual Report Amendment: Financial Highlights, Corrections, and Key SEC Filings - minichart.com.sg
Monopar (NASDAQ: MNPR) 10-K/A shows $13.7M loss but strong cash - Stock Titan
HC Wainwright Brokers Reduce Earnings Estimates for MNPR - MarketBeat
Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
MNPR SEC FilingsMonopar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MNPR's Rating Maintains 'Buy' by Chardan Capital: March 30, 2026 - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Monopar Therapeutics stock price target maintained at $104 by BTIG - Investing.com Canada
Monopar Therapeutics Inc. Q4 and Full Year 2025 Earnings: Net Loss Narrows to $13.7M - Bayelsa Watch
Monopar Therapeutics (STU:1IY0) NonCurrent Deferred Revenue : €0.00 Mil (As of Sep. 2025) - GuruFocus
Leerink reiterates Monopar stock rating on Wilson disease drug potential By Investing.com - Investing.com Canada
Raymond James reiterates Monopar stock rating on NDA timing shift By Investing.com - Investing.com Canada
Is Flanigans Enterprises Inc stock a hidden gem2026 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn
Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
MNPR: ALXN1840 advances toward NDA in 2026 as financials improve and cash reserves strengthen - TradingView
Monopar (NASDAQ: MNPR) details 2025 loss and ALXN1840 NDA plan - Stock Titan
Monopar Therapeutics (NASDAQ:MNPR) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS - MarketBeat
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - The Manila Times
Monopar Therapeutics Q4 net loss narrows on lower R&D costs - TradingView
Monopar (NASDAQ: MNPR) 10-K outlines ALXN1840 deal, pipeline and runway - Stock Titan
Monopar Therapeutics Inc. Reports Q4 and Full-Year 2025 Financial Results and Highlights Progress for ALXN1840 in Wilson Disease - Quiver Quantitative
Monopar Therapeutics 10‑K: Net loss $13.7M, EPS $(1.85) with operating loss $(16.7M) - TradingView
MNPR: Year-end cash of $140.4M supports ongoing ALXN1840 and MNPR-101 trials; net loss was $13.7M - TradingView
Wilson disease drug heads for mid-2026 filing as Monopar cash lasts to 2027 - Stock Titan
Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy - MSN
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
How Monopar Therapeutics Inc. (MNPR) Affects Rotational Strategy Timing - Stock Traders Daily
Monopar Therapeutics (MNPR) to Release Earnings on Monday - MarketBeat
US Stocks Recap: Why is Monopar Therapeutics Inc stock going downProduct Launch & Safe Swing Trade Setups - baoquankhu1.vn
BTIG Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
Monopar Therapeutics Aktie: Positive Phase 1b Data for ALXN-802 Sparks Biotech Rally on Nasdaq - AD HOC NEWS
Jones Trading Downgrades Monopar Therapeutics (MNPR) - MSN
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC - MarketBeat
(MNPR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BTIG Reiterates Buy Rating on Monopar Therapeutics (MNPR) | MNPR Stock News - GuruFocus
Published on: 2026-03-07 04:32:52 - baoquankhu1.vn
Monopar Therapeutics (MNPR) officer Susan Rodriguez submits initial Form 3 - Stock Titan
Monopar Therapeutics (MNPR) CCSO granted 48,728 stock options in new award - Stock Titan
Monopar Appoints Chief Commercial and Strategy Officer Rodriguez - The Globe and Mail
MNPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Monopar names Susan Rodriguez as chief commercial officer - Investing.com India
Monopar names Susan Rodriguez as chief commercial officer By Investing.com - Investing.com Australia
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):